Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 53-63 , January 2006

[11C]SMe-ADAM, an imaging agent for the brain serotonin transporter: synthesis, pharmacological characterization and microPET studies in rats

  • Jörg Zessin

      Affiliations

    • Institut für Bioanorganische und Radiopharmazeutische Chemie, Forschungszentrum Rossendorf, 01314 Dresden, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 351 260 2807; fax: +49 351 260 12807.
    • ,
  • Winnie Deuther-Conrad

      Affiliations

    • Institut für Interdisziplinäre Isotopenforschung, 04318 Leipzig, Germany
    • ,
  • Marion Kretzschmar

      Affiliations

    • Institut für Bioanorganische und Radiopharmazeutische Chemie, Forschungszentrum Rossendorf, 01314 Dresden, Germany
    • ,
  • Frank Wüst

      Affiliations

    • Institut für Bioanorganische und Radiopharmazeutische Chemie, Forschungszentrum Rossendorf, 01314 Dresden, Germany
    • ,
  • Beate Pawelke

      Affiliations

    • Institut für Bioanorganische und Radiopharmazeutische Chemie, Forschungszentrum Rossendorf, 01314 Dresden, Germany
    • ,
  • Peter Brust

      Affiliations

    • Institut für Interdisziplinäre Isotopenforschung, 04318 Leipzig, Germany
    • ,
  • Jörg Steinbach

      Affiliations

    • Institut für Interdisziplinäre Isotopenforschung, 04318 Leipzig, Germany
    • ,
  • Ralf Bergmann

      Affiliations

    • Institut für Bioanorganische und Radiopharmazeutische Chemie, Forschungszentrum Rossendorf, 01314 Dresden, Germany

Received 24 February 2005 ,Revised 14 July 2005 ,Accepted 16 July 2005.

References 

  1. Laruelle M, Vanisberg MA, Maloteaux JM. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol Psychiatry. 1988;24:299–309
  2. Bäckström I, Bergström M, Marcusson J. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res. 1989;486:261–268
  3. Healy D. The antidepressant era. Cambridge, MA: Harvard University Press; 1999;
  4. Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a population based sample of depressed elderly patients. Arch Gen Psychiatry. 2003;60:897–903
  5. Ueno S. Genetic polymorphisms of serotonin and dopamine transporters in mental disorders. J Med Invest. 2003;50:25–31
  6. Brust P, Scheffel U, Szabo Z. Radioligands for the study of the 5-HT transporter in vivo. IDrugs. 1999;2:129–145
  7. Brust P, Hesse S, Müller U, Szabo Z. Neuroimaging of the serotonin transporter possibilities and pitfalls. Curr Psychiat Rev. 2006;[in press]
  8. Szabo Z, Kao PF, Scheffel U, Suehiro M, Mathews WB, Ravert HT, et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse. 1995;20:37–43
  9. Szabo Z, Scheffel U, Suehiro M, Dannals RF, Kim SE, Ravert HT, et al. Positron emission tomography of 5-HT transporter sites in the baboon brain with [11C]McN5652. J Cereb Blood Flow Metab. 1995;15:798–805
  10. Szabo Z, Scheffel U, Mathews WB, Ravert HT, Szabo K, Kraut M, et al. Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand. J Cereb Blood Flow Metab. 1999;19:967–981
  11. Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M, et al. Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatry. 2002;51:715–722
  12. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, et al. Positron emissions tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003;60:1223–1229
  13. Szabo Z, Owonikoko T, Peyrot M, Varga J, Mathews WB, Ravert HT, et al. Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biol Psychiatry. 2004;55:766–771
  14. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, et al. Long-term effects of “Ecstasy” use on serotonin transporters of the brain investigated by PET. J Nucl Med. 2003;44:375–384
  15. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, et al. A voxel-based PET investigation of the long-term effects of “ecstasy” consumption on brain serotonin transporters. Am J Psychiatry. 2004;161:1181–1189
  16. Zessin J, Eskola O, Brust P, Bergman J, Steinbach J, Lehikoinen P, et al. Synthesis of S-([18F]fluoromethyl)-(+)-McN5652 as a potential PET radioligand for the serotonin transporter. Nucl Med Biol. 2001;28:857–863
  17. Brust P, Hinz R, Kuwabara H, Hesse S, Zessin J, Pawelke B, et al. In vivo measurement of the serotonin transporter with (S)-([18F]fluoromethyl)-(+)-McN5652. Neuropsychopharmacology. 2003;28:2010–2019
  18. Brust P, Zessin J, Kuwabara H, Pawelke B, Kretzschmar M, Hinz R, et al. Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. Synapse. 2003;47:143–151
  19. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem. 2000;43:3103–3110
  20. Tarkiainen J, Vercouillie J, Emond P, Sandell J, Hiltunen J, Frangin Y, et al. Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter. J Label Compd Radiopharm. 2001;44:1013–1023
  21. Huang Y, Hwang DR, Narendran R, Sudo Y, Chatterjee R, Bae SA, et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab. 2002;22:1377–1398
  22. Huang Y, Narendran R, Bae SA, Erritzoe D, Guo N, Zhu Z, et al. A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11C]AFA). Nucl Med Biol. 2004;31:727–738
  23. Zhu Z, Guo N, Narendran R, Erritzoe D, Ekelund J, Hwang DR, et al. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl Med Biol. 2004;31:983–994
  24. Jarkas N, McConathy J, Votaw JR, Voll RJ, Malveaux E, Camp VM, et al. Synthesis and characterization of EADAM: a selective radioligand for mapping brain serotonin transporters by positron emission tomography. Nucl Med Biol. 2005;32:75–86
  25. Huang Y, Zhu H, Bae SA, Hwang DR, Narendran R, Phan V, et al. Comparison of three F-18 labeled PET ligands for the serotonin transporter: radiosynthesis and in vivo imaging studies in baboon. J Label Compd Radiopharm. 2003;46:S57
  26. Shiue GG, Choi SR, Fang P, Hou C, Acton PD, Cardi C, et al. N,N-dimethyl-2-(2-amino-4-18F-fluorophenylthio)-benzylamine (4-18F-ADAM): an improved PET radioligand for serotonin transporters. J Nucl Med. 2003;44:1890–1897
  27. Oya S, Choi SR, Coenen H, Kung HF. New PET imaging agent for the serotonin transporter: [18F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). J Med Chem. 2002;45:4716–4723
  28. Fang P, Shiue GG, Shimazu T, Greenberg JH, Shiue CY. Synthesis and evaluation of N,N-dimethyl-2-(2-amino-5-[18F]fluorophenylthio)benzylamine (5-[18F]-ADAM) as a serotonin transporter imaging agent. Appl Radiat Isot. 2004;61:1247–1254
  29. Schindelbauer H. Reaktionen mit Dimethylformamid 1. Mitt. Monatsh Chem. 1968;99:1799–1807
  30. Lynch D, Miller J, Spawn T. A convenient synthesis of 2-methyl-5-(methylthio)benzothiazole. Synth Commun. 1997;27:897–905
  31. Bourquin J, Schwarb G, Gamboni G, Fischer R, Ruesch L, Guldimann S, et al. N-substituierte Mercapto-azaphenothiazin-Derivate. Helv Chim Acta. 1959;272:2541–2547
  32. Crouzel C, Långström B, Pike V, Coenen H. Recommendations for a practical production of [11C] methyl iodide. Appl Radiat Isot. 1987;38:601–603
  33. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, et al. Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain. Synapse. 2000;38:403–412
  34. Hummerich R, Reischl G, Ehrlichmann W, Machulla HJ, Heinz A, Schloss P. DASB - in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer. J Neurochem. 2004;90:1218–1226
  35. Chalon S, Tarkiainen J, Garreau L, Hall H, Emond P, Vercouillie J, et al. Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity. J Pharmacol Exp Ther. 2003;304:81–87
  36. Huang Y, Hwang DR, Bae SA, Sudo Y, Guo N, Zhu Z, et al. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). Nucl Med Biol. 2004;31:543–556
  37. Marjamäki P, Zessin J, Eskola O, Grönroos T, Haaparanta M, Bergman J, et al. S-[18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats. Synapse. 2003;47:45–53
  38. Chen HT, Clark M, Goldman D. Quantitative autoradiography of 3H-paroxetine binding sites in rat brain. J Pharmacol Toxicol Methods. 1992;27:209–216
  39. Scheffel U, Hartig PR. In vivo labeling of serotonin uptake sites with [3H]paroxetine. J Neurochem. 1989;52:1605–1612
  40. Cumming P, Kretzschmar M, Brust P, Smith DF. Quantitative radioluminography of serotonin uptake sites in the porcine brain. Synapse. 2001;39:351–355
  41. Suehiro M, Scheffel U, Ravert HT, Dannals RF, Wagner HN. [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci. 1993;53:883–892
  42. Wilson AA, Ginovart N, Hussey D, Meyer J, Houle S. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol. 2002;29:509–515
  43. Plisson C, McConathy J, Martarello L, Malveaux EJ, Camp VM, Williams L, et al. Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2β-carbomethoxy-3β-[4′-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter. J Med Chem. 2004;47:1122–1135
  44. Suhara T, Sudo Y, Yoshida K, Okubo Y, Fukuda H, Obata T, et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet. 1998;351:332–335
  45. Lee SL, Fanburg BL. Serotonin uptake by bovine pulmonary artery endothelial cells in culture. I. Characterization. Am J Physiol. 1986;250:C761–C765
  46. Wakayama K, Ohtsuki S, Takanaga H, Hosoya K, Terasaki T. Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells. Neurosci Res. 2002;44:173–180
  47. Brust P, Friedrich A, Krizbai IA, Bergmann R, Roux F, Ganapathy V, et al. Functional expression of the serotonin transporter in immortalized rat brain microvessel endothelial cells. J Neurochem. 2000;74:1241–1248
  48. Bennett-Clarke CA, Chiaia NL, Rhoades RW. Thalamocortical afferents in rat transiently express high-affinity serotonin uptake sites. Brain Res. 1996;733:301–306
  49. Bunin MA, Prioleau C, Mailman RB, Wightman RM. Release and uptake rates of 5-hydroxytryptamine in the dorsal raphe and substantia nigra reticulata of the rat brain. J Neurochem. 1998;70:1077–1087
  50. Cabrera-Vera TM, Battaglia G. Prenatal exposure to fluoxetine (Prozac) produces site-specific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. J Pharmacol Exp Ther. 1998;286:1474–1481
  51. Coulter CL, Happe HK, Bergman DA, Murrin LC. Localization and quantification of the dopamine transporter: comparison of [3H]WIN 35,428 and [125I]RTI-55. Brain Res. 1995;690:217–224
  52. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363–375
  53. Szyndler J, Wierzba-Bobrowicz T, Maciejak P, Siemiatkowski M, Rook P, Lehner M, et al. Pentylenetetrazol-kindling of seizures selectively decreases [3H]-citalopram binding in the CA-3 area of rat hippocampus. Neurosci Lett. 2002;335:49–53

PII: S0969-8051(05)00197-6

doi: 10.1016/j.nucmedbio.2005.07.009

Nuclear Medicine and Biology
Volume 33, Issue 1 , Pages 53-63 , January 2006

Article Tools

* Image Usage & Resolution